--Community Trust Bancorp Keeps Quarterly Dividend at $0.47 a Share, Payable April 1 to Holders of Record on March 15-February 2024-www.financetom.com

--Community Trust Bancorp Keeps Quarterly Dividend at $0.47 a Share, Payable April 1 to Holders of Record on March 15

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

--Community Trust Bancorp Keeps Quarterly Dividend at $0.47 a Share, Payable April 1 to Holders of Record on March 15

Jan 29, 2025 7:46 AM

10:18 AM EST, 01/29/2025 (MT Newswires) --

Price: 54.20, Change: +0.67, Percent Change: +1.25

Previous page： BRIEF-Genmab To Buy Merus For USD 8.0 Billion Next page：

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

BRIEF-Genmab To Buy Merus For USD 8.0 Billion

Sep 28, 2025

Sept 29 (Reuters) - Genmab A/S ( GMAB ): * GENMAB TO ACQUIRE MERUS, EXPANDING LATE-STAGE PIPELINE AND ACCELERATING INTO A WHOLLY OWNED MODEL * GENMAB A/S ( GMAB ) - TO BUY MERUS FOR USD 8.0 BILLION * GENMAB A/S ( GMAB ) - DEAL EXPECTED TO BE ACCRETIVE TO EBITDA BY 2029 * GENMAB A/S ( GMAB )...

Sep 28, 2025

...

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Sep 28, 2025

Company Announcement Genmab ( GMAB ) to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab ( GMAB ) to host a...

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Sep 28, 2025

Company Announcement Genmab ( GMAB ) to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab ( GMAB ) to host a conference...